Exscientia is sprinting to win the great AI biotech race. The UK company, having long labored on small discovery deals with large pharmas, raised up to $525 million in a Series D led by the infamous Japanese conglomerate SoftBank in April and followed it up less than a month later with a Bristol Myers Squibb … Continue reading Exscientia spends SoftBank’s cash in bid to edge out AI rivals